0001192482-18-000109.txt : 20180313 0001192482-18-000109.hdr.sgml : 20180313 20180313161559 ACCESSION NUMBER: 0001192482-18-000109 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180309 FILED AS OF DATE: 20180313 DATE AS OF CHANGE: 20180313 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Berelowitz Michael CENTRAL INDEX KEY: 0001493383 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36329 FILM NUMBER: 18686642 MAIL ADDRESS: STREET 1: 415 EAST 37TH STREET STREET 2: APT 36C CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Recro Pharma, Inc. CENTRAL INDEX KEY: 0001588972 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261523233 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (484) 395-2400 MAIL ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-03-09 0001588972 Recro Pharma, Inc. REPH 0001493383 Berelowitz Michael C/O RECRO PHARMA, INC. 490 LAPP ROAD MALVERN PA 19355 1 0 0 0 Common Stock 2018-03-09 4 M 0 7500 2.47 A 7500 D Common Stock 2018-03-09 4 S 0 7500 10.4462 D 0 D Stock Option (right to buy) 2.47 2018-03-09 4 M 0 7500 0 D 2024-12-17 Common Stock 7500 14500 D The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.411 to $10.5053, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. The option vested on December 17, 2015. Exhibit List: Exhibit 24 - Power of Attorney /s/ Ryan Lake, as Attorney-in-Fact 2018-03-13 EX-24 2 poaberelowitz.htm POA
                                POWER OF ATTORNEY



 Know all by these presents, that the undersigned hereby constitutes and

appoints the Chief Executive Officer, the Chief Financial Officer and Chief

Accounting Officer of Recro Pharma, Inc. (the "Company"), each as the undersigned's

true and lawful attorney-in-fact to:



 (1)   execute for and on behalf of the undersigned, in the undersigned's

capacity as an officer and/or director of the Company,Forms 3 and 4, in accordance

with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;



 (2)  do and perform any and all acts for and on behalf of the undersigned

which may be necessary or desirable to (A) complete and execute any such Forms 3

or 4 (B), complete and execute any amendment or amendments thereto, and (C) timely

file such forms with the United States Securities and Exchange Commission and

any stock exchange or similar authority; and



 (3)  take any other action of any type whatsoever in connection with the

foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,

in the best interest of, or legally required by, the undersigned, it being

understood that the documents executed by such attorney-in-fact on behalf

of the undersigned pursuant to this Power of Attorney shall be in such

form and shall contain such terms and conditions as such attorney-in-fact may

approve in such attorney-in-fact's discretion.



 The undersigned hereby grants to each such attorney-in-fact full power

and authority to do and perform any and every act and thing whatsoever requisite,

necessary or proper to be done in the exercise of any of the rights and powers

herein granted, as fully to all intents and purposes as the undersigned might

or could do if personally present, with full power of substitution or revocation,

hereby ratifying and confirming all that such attorney-in-fact, or such

attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be

done by virtue of this Power of Attorney and the rights and powers herein granted.



 The undersigned acknowledges that the foregoing attorney-in-fact, in

serving in such capacity at the request of the undersigned, is not assuming,

nor is the Company assuming, any of the undersigned's responsibilities to comply

with Section 16 of the Securities Exchange Act of 1934.





 This Power of Attorney shall remain in full force and effect until the

undersigned is no longer required to file Forms 3, 4, and 5 with respect to

the undersigned's holdings of and transactions in securities issued by the

Company, unless earlier revoked by the undersigned in a signed writing delivered

to the foregoing attorneys-in-fact.



 IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney

to be executed as of this 12th day of March, 2018.









    By: /s/ Michael Berelowitz

    Name:   Michael Berelowitz